How the NITI Aayog Wake-Up Call Is Unlocking a Generational Startup Window in Pharma Manufacturing
India API Import Problem
India is proud of the title, Pharmacy of the World. It provides almost half of Africa’s generic medicines requirements, 40% of the demand in the USA for generic medicines and 25% of the UK’s generic medicines demand. But there’s a disturbing contradiction at the heart of this proud story.
The government’s own think tank, NITI Aayog, has just substantiated what many industry circles have been letting the cat out of the bag for years now. India’s pharmaceutical industry is vulnerable with 65% of its demand for Active Pharmaceutical Ingredient (API) being met from China. The development is well reported in the Economic Times and more than just a policy warning. A direct market signal – and one of the most commercially relevant start-ups and MSME opportunities that has come out of the Indian industrial landscape in 2026.
The eighth edition of NITI Aayog’s Trade Watch Quarterly, recently published in The Economic Times, highlighted India’s high reliance on China for Active Pharmaceutical Ingredients (APIs), Key Starting Materials (KSMs), and intermediates, particularly in the pharmaceutical industry, which extensively uses fermentation-based products. To the founders who know supply chain economics, it’s not a policy headline. It is a market worth of ₹27,000 crore every year which is an indicator for the country towards a more domestic manufacturing industry as the most pressing issue.
Use this article as your business intelligence guide to understand the market shift, explore current government policies and what they actually allow, and discover actionable business ideas for startups and MSMEs that are ready to take action.
Get Detailed Project Report (DPR): Active Pharmaceutical Ingredient (API) Products, Bulk API Manufacturing
What Recent Economic Times Reporting Means
The Economic Times’ report of June 24, 2026, marked a landmark moment because NITI Aayog officially recognized the structural vulnerability of India’s pharmaceutical supply chain and highlighted the need to address it. The complete report can be found here: Economic Times — India’s Pharma Supply Chain Dependent on Chinese Imports: NITI Aayog.
The Core Finding
This was clearly spelt out in the NITI Aayog’s report – India relies on China for 65% of its APIs and Key Starting Materials. In the case of products made by fermentation, the reliance is almost absolute, as this is the foundation of antibiotic production. This is nothing new; it’s been there for years in import. Now what is new is the sense of urgency and clarity of policy that now surround it.(India API Import Problem)
Why This Changes the Market for Founders
Publishing a directional report such as this one is a multi-layered exercise by NITI Aayog. It makes domestic production of APIs a national priority. It indicates that future policy measures – funding, licensing, infrastructure – will support this. And it is telling to global buyers of pharmaceuticals that India is making a concerted effort to establish an alternative supply chain to China.
The MSME and Startup Implication
This problem isn’t a one-man job for India’s large pharmaceutical companies. The API manufacturing ecosystem relies on decades of niche players, including contract manufacturers, fermentation specialists, KSM processors, quality testing labs, cold chain operators, and regulatory consultants. All of these are an opportunity for an MSME or start-up. The Economic Times report is really announcing the opening bell for a new manufacturing cycle.
Why This Industry Is Growing — Right Now
The Indian API and bulk drug manufacturing industry isn’t growing due to optimistic projections. It is increasing in size due to functional requirements. Explore these overlapping forces that all founders must deal with:
The Scale of the Gap
India’s API imports from China rose by nearly 45% from ₹18,646 crore in 2020-21 to ₹27,032 crore in 2024-25. Meanwhile, the Indian API market will grow from USD 14.18 billion in 2025 to USD 22.18 billion by 2031, registering a CAGR of 7.74% during the forecast period. Demand will grow. Whether or not Chinese factories are able to fulfil that demand or if it is India’s factories that are able to do so.(India API Import Problem)
Get Detailed Insights from This Book: Biotech & Pharmaceutical Handbook
The China-Plus-One Effect
There is a push by global pharmaceutical companies, particularly in the United States and in Europe, to de-risk their supply chain from China. In 2024 alone, Indian Contract API manufacturers have experienced a 50% surge in Request for Quotations (RFQs) since the passage of the US Biosecure Act, which bans the use of certain Chinese biotech companies by federal contractors. This is not “supply-side” demand. These are genuine buyers who have genuine procurement budgets that are moving towards India.
The Patent Cliff Tailwind
By 2030 more than 190 blockbuster drugs are projected to lose their patents. The expiry every time presents the opportunity for Indian generic drug makers and each generic drug depends on APIs. The new API demands due to the patent cliff are forming a structural wave which will keep the market growing well beyond the next budget cycle.(India API Import Problem)
The Economic Times has been consistently monitoring the export performance of Indian pharmaceuticals. Pharmaceutical exports to India grew by 9.4% year-on-year to USD 30.47 billion in FY2024-25. This is proof of a genuine and growing demand for Indian pharmaceutical products and hence the Indian-made APIs in the world.
Government Policies and Incentives
The policy landscape for the Indian pharma manufacturing industry is more pro-commercial than ever. The central Government has supported three large-scale plans that work together to offer an unparalleled system of support for founders.
1. PLI Scheme for Bulk Drugs — ₹6,940 Crore
The Production Linked Incentive scheme for critical APIs and KSMs provides for 10–20% incentive on incremental domestic sales for 6 years. The scheme aims at covering 41 identified critical bulk drugs. Information and applications can be obtained from Department of Pharmaceuticals — PLI Scheme. Under this scheme, the government has selected 48 projects and commissioned 34 projects, with a committed investment of more than ₹4,155 crore. (India API Import Problem)
2. Bulk Drug Parks Scheme — ₹3,000 Crore
The Central government is working on establishing three Mega Bulk Drug Parks in Andhra Pradesh, Gujarat and Himachal Pradesh. The Centre provides 70-90% of the finances for common infrastructure (utilities, effluent treatment plant, solvent recovery unit). This lowers the number one cost challenge for new entrants – installing environmental compliance infrastructure.
Choose the right startup backed by real market demand
3. PLI for Pharmaceuticals — ₹15,000 Crore
A liberalised PLI scheme with an outlay of ₹15,000 crore covers the manufacture of high value pharmaceuticals such as biopharmaceuticals, oncology drugs, auto-immune drugs and patented drugs. This scheme aims to help Indian manufacturers move to the next level in the value chain, aligning with the recommendations in NITI Aayog’s latest report.(India API Import Problem)
4. Startup India Benefits
Tax exemptions of 3 years on tax benefits, fast-track IP filing and access to the Fund-of-Funds (FoF) of ₹10,000 crore are provided to DPIIT registered pharma startups. The Startup India Portal enables a simplified registration process for life science startups.
5. MSME and SIDBI Support
SIDBI provides pharma industry MSMEs with loans in the priority sector and loans for technology upgradations. CGTMSE provides collateral-free credit of up to ₹5 crore, while MUDRA Tarun loans can be availed for up to ₹20 lakh for the start of business. These programmes are automatically unlocked once the Udyam registration takes place in MSME.gov.in.
Business Ideas for Startups and MSMEs — Emerging from the NITI Aayog Signal
The next 6 business models are not about ideas. They spring from the actual gap in the market that NITI Aayog and Economic Times have now put on record. Both tackle a particular problem in India’s drug supply chain vulnerability.(India API Import Problem)
1. Fermentation-Based Antibiotic API Manufacturing
India imports almost 100% of the fermentation-based APIs required for the production of antibiotics such as Penicillin G, Cephalosporins, and Rifampicin intermediates. It’s these higher dependency, higher urgency segments. The fermentation unit is available for PLI incentives, Bulk Drug Park infrastructure, and US/EU export contracts once the unit is set-up with GMP certification. Average investment: ₹50 crore or more. Timeline to commercialisation: PLI support 24-36 months.
2. KSM and Drug Intermediate Manufacturing
Key Starting Materials are the chemicals that are used for the synthesis of APIs. India is a major importer of KSMs from China at present. Setting up a KSM processing unit (for a limited number of well-defined molecules, 5–10) is a feasible entry point for MSMEs. Synthetic KSMs can be created at a cost of ₹15-30 crore. Shared infrastructure of government funded Bulk Drug Parks significantly reduces upfront costs.(India API Import Problem)
3. Contract Research and Manufacturing Services (CRAMS) for API Startups
Indian companies are eager to get qualified by global companies but are unable to deal with the regulatory complexity on their own. A niche CRAMS company that helps with regulatory filings, GMP audit preparation, analytical testing and supply chain consulting is just between the big pharma buyers and the small Indian API manufacturers. Service based, capital intensive and highly exportable.
4. Regulatory Compliance and Quality Testing Laboratories
All API manufacturing sites need third party quality testing and regulatory compliance documentation of US FDA, EU EMA and WHO GMP certification. India’s fast-growing API manufacturing growth will generate a need for a dozen independent testing laboratories. The advantage of this model is that it is comparatively of low investment (between ₹5 and ₹15 crore) and has a fixed recurring income from manufacturing clients.
5. Pharma Cold Chain and API Logistics Infrastructure
APIs are delicate materials that need to be stored and transported in a temperature-controlled environment. The specialised pharmaceutical cold chain logistics requirement will escalate in proportion to the scaling up of domestic API manufacturing in Bulk Drug Parks in three States. An MSME that positions itself as a dedicated logistical partner in the pharma value chain, providing GMP compliant warehousing, GPS tracked transport and regulatory paperwork, fills a gap in the value chain.(India API Import Problem)
Related Article: API MANUFACTURING: Setting Up an Active Pharmaceutical Ingredient Plant in India: The Complete Guide
6. Biopharma and Biosimilar API Development
NITI Aayog’s report specifically urges India to scale up into the higher value segments of the pharmaceutical value chain. Biopharma SHAKTI is a government scheme of Rs 10,000 crore to support the development of biologics, biosimilars and biopharmaceuticals. Having the funding stream open is an opportunity for a company to start its API development business around molecules off patent in the 2027-30-time frame and develop export-ready expertise.
Import–Export Opportunity Analysis
The Import Substitution Story
India imports around ₹27,032 crore worth of APIs every year from China. A mere 10-15% of this import substitution opportunity translates into a ₹2,700-4,000 crore domestic manufacturing market for new players. The financial bridge is provided by the PLI scheme, the infrastructure by the Bulk Drug Parks and the policy direction by the NITI Aayog.
The Export Growth Story
As reported in the Economic Times, India’s pharmaceutical exports reached USD 30.47 billion in the last year (2024-25). US and EU buyers are adopting ‘China Plus One’ policy that is generating direct RFQ for Indian API suppliers. pharmexcil actively helps the Indian API exporters for market development support and buyer-seller meets through the Export Promotion Council for Chemicals and Pharmaceuticals (Pharmexcil). Any new API manufacturer that has received USFDA or EU GMP certification will be able to access export orders that are now going to China.
High-Value Export Segments to Target
- APIs are generally considered high value, of growing demand worldwide, with a relatively small level of direct competition in China at a quality level.
- Anti-diabetic APIs — GLP-1 receptor agonist molecules experiencing explosive worldwide demand
- Cardiovascular APIs — Cliff of the future generic API demand drugs
- Fermentation APIs for anti-infective drugs such as Penicillin G and Cephalosporin intermediates (critical gap)
- The biopharmaceutical APIs segment includes biosimilars for blockbuster biologics in imminent loss of exclusivity by 2030.The biopharmaceutical APIs segment encompasses biosimilars for blockbuster biologic drugs slated to lose exclusivity by 2030.
Indian MSME Success Stories — Proof the Model Works
Macsen Labs, Udaipur — MSME to Export Leader
Macsen Labs started as a small API makers company in Rajasthan and has grown up to become a USFDA approved, WHO-GMP and TGA-GMP facility. The company is expanding as part of its groundbreaking project to build a new API facility at RIICO (Gudli) Industrial Area. The new facility will be five times the size of its current plant, and the company will fund the expansion using PLI scheme funds. For MSME-origin founders, Macsen’s journey will act as a roadmap to begin with GMP compliance, through PLI, and then into regulated export markets.
India’s Bulk Drug Park Participants — Early Movers Win
A few mid-size API manufacturers have already established their presence in the Bulk Drug Parks in Andhra Pradesh, Gujarat and Himachal Pradesh. These companies gain access to the infrastructure, shared utilities and a cluster network, all of which are available at reduced rates, while also establishing themselves as compliant and trusted producers with global buyers who are increasingly demanding compliance with cluster-based manufacturing.
The Lesson for New Founders
The moral of the two stories is the same: From the very beginning, GMP certification is a must. It is never cost effective to retrofit after the fact. Those startups that build compliance into their business from the beginning – and then grow with PLI to be competitive in regulated markets around the world – are the ones that will prevail.
About NPCS — Your Feasibility Partner for API and Pharma Projects
Starting an API manufacturing business requires more than market conviction. It requires bankable project reports, accurate capital expenditure estimates, machinery specifications, and regulatory compliance roadmaps. Niir Project Consultancy Services (NPCS) at niir.org has published comprehensive feasibility reports and techno-economic studies specifically for API and bulk drug manufacturing in India.
These reports cover plant layout design, equipment procurement lists, raw material sourcing maps, financial projections, break-even analysis, and regulatory compliance frameworks — giving founders and MSMEs a complete pre-investment assessment before committing capital. For any entrepreneur seriously considering entry into pharma manufacturing, a professionally prepared project report is the foundation of every investor conversation, every bank financing application, and every PLI scheme submission.
Market Intelligence Data Table — India API Sector 2026
| Metric | Current Status | Target / Opportunity |
| China API Import Share | 65% of India’s API needs | Reduce to below 30% by 2030 |
| Annual API Import Value | ~₹27,032 crore (2024–25) | Replace with domestic production |
| Indian API Market Size | USD 14.18 billion (2025) | USD 22.18 billion by 2031 |
| PLI Scheme Outlay (Bulk Drugs) | ₹6,940 crore committed | 48 projects selected; 34 commissioned |
| PLI Scheme (Pharma overall) | ₹15,000 crore outlay | 55 selected applicants; FY27-28 |
| Bulk Drug Parks | 3 parks (AP, Gujarat, HP) | 70–90% common infra funded by Centre |
| India Global Generic Market Share | ~20% of global generics by volume | Expanding high-value drug exports |
| Fermentation API Dependency | Near 100% import for key antibiotics | Critical startup manufacturing gap |
| Pharma Export FY2024-25 | USD 30.47 billion (up 9.4%) | Target USD 50B+ by 2030 |
Frequently Asked Questions (FAQs) for Founders
1: What is the minimum investment required to start an API manufacturing unit in India?
Investment for manufacturing Synthetic APIs usually varies between 15 – 50 crore, depending on the category of API and the scale & regulation requirement. For Fermentation based APIs, a Capex of 50 crore + is needed as biological facility requirement is significant. Investing in Bulk Drug Parks (BDP) supported by the government can reduce infrastructure costs drastically and lower the barrier of entry for first-time MSME founders.
2: How does a startup access the PLI scheme for bulk drugs?
Applications are managed by the Department of Pharmaceuticals. Eligible companies must manufacture one of the 41 notified critical APIs or KSMs, demonstrate committed capital investment, and pass a technical and financial evaluation. PLI incentives are provided at 10–20% on incremental sales for six years. Founders should visit pharmaceuticals.gov.in or consult the Invest India portal for the latest application windows and product eligibility lists.
3: What certifications does an Indian API manufacturer need to export to the US and Europe?
Exporting to the United States requires US FDA Drug Establishment Registration and compliance with Current Good Manufacturing Practices (cGMP) regulations under 21 CFR Parts 210/211. European exports require EMA GMP certification. WHO GMP certification is required for exports to Africa and many Asian markets. Successful Indian export-grade API manufacturers consistently build regulatory compliance into their operations from inception rather than retrofit it later.
4: Can an MSME without prior pharma experience enter API manufacturing?
Yes — but with important caveats. The most practical entry point for non-pharma MSMEs is as a KSM or drug intermediate manufacturer, a pharmaceutical contract packaging operator, or a third-party quality testing laboratory. With the lower capital requirements, faster path through the regulatory system and giving founders the time to build out domain expertise prior to going to full API manufacturing. Early-stage pharma MSMEs are offered financing without collateral via SIDBI and CGTMSE.
5: What does the NITI Aayog report mean for import substitution startups?
NITI Aayog’s Trade Watch Quarterly provides confirmation that, we’ll see direct import substitution as a state goal with government preference on approvals and long-term procurement as a result – supply chain gap identified by a nation’s premier advisory institution can trigger enduring commercial tailwind for the memes and startups in the segment. This is more about government affirmation than mere data.
6: What is the role of the Pharmexcil in supporting API exporters?
Support in Market Development and Buyer-Seller Linkages, Facilitating your Participation at International Pharma Exhibitions, Assistance for Export Documentation and Many More – that is what the Pharmaceutical Export Promotion Council of India (Pharmexcil) offers to all its esteemed members. For API manufacturers targeting international markets, Pharmexcil membership is a practical first step in building global buyer relationships and accessing export facilitation schemes from the Ministry of Commerce.
Conclusion — The Window Is Open. Act Before It Narrows.
Economic Times and NITI Aayog have together done founders a favour this week. They have confirmed, in the clearest possible terms, that India’s ₹27,000 crore API import dependence on China is a known structural vulnerability — and that the policy ecosystem to address it is firmly in place.
The PLI scheme has committed ₹6,940 crore. Bulk Drug Parks are under construction in three states. Global buyers are shifting RFQs to India. The patent cliff is creating a decade of sustained API demand. And NITI Aayog’s latest report has just made domestic API manufacturing a stated national priority.
What more does a founder need to act?
The honest answer is: not much. What separates founders who capitalise on this from those who wait and watch is execution speed. In pharmaceutical manufacturing, regulatory timelines are long. A company that begins its GMP-compliant API manufacturing facility today will be production-ready in 24–30 months — positioned exactly at the inflection point when India’s policy push translates into full market traction.
India has always been the Pharmacy of the World in name. With the right founder action today, it will be the Pharmacy of the World in raw material supply as well. That is the signal Economic Times and NITI Aayog sent this week. The market is listening. The question is — are you?
Sources & Key References
Economic Times — Pharma & Life Sciences | Startup India | MSME Ministry | SIDBI | Pharmexcil
